Mr. David Regan reports

SONA NANOTECH GRANTS OPTIONS

Sona Nanotech Inc. has granted 1,195,000 incentive stock options under the company's stock option plan, of which 810,000 have been granted to a directors and officers. Each option is exercisable into one common share at a price of 31 cents per share and will vest at the rate of 25 per cent every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the company's stock option plan.

About Sona Nanotech Inc.

Sona Nanotech, a nanotechnology life sciences company, is developing targeted hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumour and re-emitted as heat. Therapeutic heat (41 C to 48 C) stimulates the immune system, shrinks tumours, inactivates cancer stem cells and increases tumour perfusion -- thus enabling drugs to reach all tumour compartments more effectively. The size, shape and surface chemistry of the nanorods target the leaky vasculature of solid tumours, and the selective thermal sensitivity of tumour tissue enables the therapy to deliver clean margins. Targeted hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles, which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are free of cetyltrimethylammonium (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the U.S. Food and Drug Administration (FDA).

We seek Safe Harbor.